SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
阿斯利康(US:AZN) Businesswire·2025-09-17 19:05WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus (SLE) showed that the subcutaneous (SC) administration of AstraZeneca's SAPHNELO® (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.1 The safety profile observed in the interim analysis was consistent with the known clinical profile of SAP. ...